1. Monoclonal Antibody Therapy in Sinonasal Disease
- Author
-
Sergio E. Chiarella, Anju T. Peters, and Hendrik Sy
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Chronic rhinosinusitis ,Population ,Omalizumab ,Antibodies, Monoclonal, Humanized ,03 medical and health sciences ,Nasal Polyps ,0302 clinical medicine ,otorhinolaryngologic diseases ,Humans ,Immunology and Allergy ,Medicine ,Nasal polyps ,Sinusitis ,education ,Monoclonal antibody therapy ,Rhinitis ,education.field_of_study ,Interleukin-13 ,biology ,business.industry ,Antibodies, Monoclonal ,General Medicine ,Immunoglobulin E ,respiratory system ,medicine.disease ,Sinonasal disease ,Dermatology ,030104 developmental biology ,Chronic disease ,030228 respiratory system ,Otorhinolaryngology ,Chronic Disease ,Monoclonal ,Immunology ,biology.protein ,Immunotherapy ,Interleukin-4 ,Interleukin-5 ,Antibody ,business - Abstract
Chronic rhinosinusitis (CRS) affects 12.5% of the U.S. population. CRS can be divided into CRS with nasal polyps (CRSwNP) and CRS without nasal polyps. Some individuals with CRSwNP do not respond to standard-of-care medical and surgical management. For these individuals, targeted biologic agents are emerging as an important therapeutic alternative. In this review, we described the most-relevant studies that addressed the use of anti-immunoglobulin E (omalizumab), anti-interleukin 5 (mepolizumab and reslizumab), and anti-interleukin 4/interleukin 13 (dupilumab) monoclonal antibodies for the treatment of CRSwNP. In addition, we discussed the importance of some of these clinical trials in identifying new CRS endotypes based on distinct inflammatory profiles.
- Published
- 2017